Clinical trial · Interventional
Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects
A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for 4 Weeks for the Treatment of Common Warts in Pediatric Subjects
NCT00116675CI-TRIAL-00000606completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of three different strengths of resiquimod gel applied to common wart(s) three times a week for four weeks. A second purpose is to evaluate the safety of the drug.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Warts | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Resiquimod | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Clearance of treated wart(s)
Secondary outcomes (2)
- measure
- Partial clearance of treated wart(s)
- measure
- Wart recurrence
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 3 Years
- Maximum age
- 11 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of common warts * Ages between 3 to 11 Exclusion Criteria: * Other types of wart(s), ie. plantar * Currently participating in another clinical study * Chronic viral hepatitis B or C
References
Publications (0)
Data not yet available
No reference posted for this study.